Search

Shah: Acetylon: Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Speakers Bureau; Spectrum: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; PLexus Communications: Honoraria; Bayer: Honoraria; Rosetta Genomics: Research Funding; Seattle Genetics: Research Funding. Komrokji:Novartis: Research Funding, Speakers Bureau; Pharmacylics: Speakers Bureau; Incyte: Consultancy; Celgene: Consultancy, Research Funding. Lancet:Amgen: Consultancy; Kalo-Bios: Consultancy; Seattle Genetics: Consultancy; Celgene: Consultancy, Research Funding; Boehringer-Ingelheim: Consultancy; Pfizer: Research Funding.

Background

Background: ALL is an aggressive hematologic malignancy traditionally treated with intensive inpatient-based chemotherapy, which can require prolonged hospitalizations both for the delivery of chemotherapy and subsequent side effects including infectious complications and cytopenias. In addition, chemotherapeutic CNS prophylaxis further intensifies the regimen and the logistical challenges associated with its delivery. While inpatient delivery of chemotherapy may mitigate some of the logistical and clinical challenges, as healthcare moves towards a value oriented approach, delivery of these services in an outpatient setting that could lower the cost of care may offer significant value to the patient and institution. We report on our institutional experience of shifting the commonly used Hyper-CVAD regimen ("Arm-A") into the outpatient setting.

Komrokji: Celgene: Consultancy, Research Funding; Incyte: Consultancy; Novartis: Research Funding, Speakers Bureau; Pharmacylics: Speakers Bureau. Sokol:Seatle Genetics: Research Funding; Celgene: Consultancy; Spectrum: Consultancy.